Affinage

SOX17

Transcription factor SOX-17 · UniProt Q9H6I2

Length
414 aa
Mass
44.1 kDa
Annotated
2026-06-10
100 papers in source corpus 46 papers cited in narrative 46 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/8 claims corpus-supported (88%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SOX17 is an HMG-box transcription factor that directly binds Sox consensus DNA elements to control gene-expression programs across endoderm, vascular, hematopoietic, and germ-cell lineages (PMID:15220343, PMID:32894225, PMID:25373912). Its activity is governed by a dual relationship with the Wnt pathway: a conserved C-terminal SoxF motif binds β-catenin to potentiate transactivation of endodermal targets such as Foxa1/Foxa2 (PMID:15163629), and genome-wide co-occupancy with β-catenin makes SOX17 a tissue-specific modifier of Wnt responses, synergizing at some enhancers while restricting transcription at others (PMID:32894225); in other cellular contexts SOX17 antagonizes Wnt signaling by binding TCF/LEF through its HMG box and driving proteasomal degradation of β-catenin and TCF, or by directly repressing the β-catenin and Lef-1 promoters (PMID:17875931, PMID:20802155, PMID:29970906). SOX17 also restrains TGF-β signaling by binding Smad3 and blocking its DNA binding while activating cyclin D1 to drive cell-cycle progression (PMID:19479035). In the vasculature SOX17 specifies and maintains arterial identity, acting downstream of canonical Wnt and upstream of Notch, and controls hemogenic endothelium, tip-cell behavior, VEGFR2 expression, and barrier integrity (PMID:24153254, PMID:23604320, PMID:24755984, PMID:30591003). It is required for fetal/neonatal HSC identity and intra-aortic cluster maintenance, where it acts as an on/off switch between self-renewal and differentiation, and drives the CDX2/HOXA arterial-hematopoietic program in hemogenic endothelium (PMID:17655922, PMID:24662049, PMID:33596423). SOX17 is a master regulator of human primordial germ cell specification acting with TFAP2C downstream of BMP/GATA effectors (PMID:25543152, PMID:33608411), and directs endoderm-derived organ lineages including biliary/gallbladder, pancreatic β-cell secretory function, and uterine epithelial-stromal crosstalk via an Ihh enhancer (PMID:19913509, PMID:25144761, PMID:30356064). In disease, reduced SOX17 underlies pulmonary arterial hypertension—through risk variants that impair HOXA5/ROR-α binding at SOX17 regulatory elements and downstream activation of HGF/c-Met and E2F1 signaling—while in cancer SOX17 can act as a tumor suppressor or, in colorectal tumors, drive an immune-evasive fetal program (PMID:37066790, PMID:36205124, PMID:37737027, PMID:38418875). SOX17 protein is stabilized by the deubiquitinase UCHL1 (PMID:38478109).

Mechanistic history

Synthesis pass · year-by-year structured walk · 42 steps
  1. 2004 High

    Established how SOX17 engages both DNA and a transcriptional cofactor: it binds Sox sites via its HMG box and physically associates with β-catenin through a conserved SoxF C-terminal motif to activate endodermal genes.

    Evidence Co-IP, EMSA, reporter/transactivation assays and mutagenesis in Xenopus embryos, cell lines, and F9 cells

    PMID:15163629 PMID:15220343

    Open questions at the time
    • Does not resolve how the same protein switches between β-catenin co-activation and antagonism
    • Structural basis of the SoxF-β-catenin interface not defined
  2. 2007 High

    Revealed the antagonistic arm of SOX17-Wnt crosstalk, showing SOX17 binds TCF/LEF and promotes GSK3β-independent, proteasome-dependent degradation of β-catenin and TCF.

    Evidence Co-IP, TCF/LEF reporter assays, gain/loss-of-function and proteasome inhibition in SW480 colon carcinoma cells

    PMID:17875931

    Open questions at the time
    • Ubiquitin ligase mediating degradation not identified
    • Determinants selecting activation vs. degradation context unknown
  3. 2006 High

    Extended SOX17 function beyond endoderm by showing it drives oligodendrocyte progenitor cell-cycle exit and differentiation and activates the MBP promoter.

    Evidence siRNA knockdown and overexpression with reporter assays in FACS-purified oligodendrocyte lineage cells

    PMID:16988043

    Open questions at the time
    • Direct vs. indirect MBP regulation not fully resolved
    • Pathway linkage to Notch/TCF7L2 not yet established at this stage
  4. 2007 High

    Defined a developmental-stage-specific requirement for SOX17 in hematopoiesis, showing it maintains fetal/neonatal but not adult HSCs.

    Evidence Germline and conditional Cre/lox deletion with flow cytometry and transplantation

    PMID:17655922

    Open questions at the time
    • Mechanism of the fetal-to-adult HSC switch and Sox17 silencing not defined
    • Direct target genes in HSCs not identified
  5. 2007 Medium

    Placed SOX17 in cardiac mesoderm specification, acting downstream of mesoderm formation but upstream of Mesp1/2 and Hex.

    Evidence Lentiviral shRNA knockdown in differentiating ES cells with lineage-marker RT-PCR

    PMID:17360443

    Open questions at the time
    • Non-cell-autonomous signal identity not defined here
    • Direct targets not mapped at this stage
  6. 2009 High

    Identified a TGF-β-restraining function: SOX17 binds Smad3 to block its DNA binding while activating cyclin D1, coupling SOX17 to proliferation control in lung epithelium.

    Evidence Co-IP, cyclin D1 promoter reporter assays, and conditional Sox17 expression in adult mouse lung

    PMID:19479035

    Open questions at the time
    • Whether Smad3 inhibition is direct competition or sequestration not resolved
    • Generality across tissues not tested
  7. 2009 Medium

    Mapped upstream regulation of Sox17, showing Oct4 redistributes from the Sox2 to the Sox17 promoter during cardiac progenitor specification to generate a paracrine endodermal source.

    Evidence ChIP/promoter occupancy, Oct4 overexpression, and paracrine conditioned-medium rescue in human ES cells

    PMID:19736317

    Open questions at the time
    • Mechanism driving Oct4 promoter switch unknown
    • Single-lab system
  8. 2010 High

    Demonstrated direct transcriptional Wnt antagonism by SOX17 at the Lef-1 promoter, with both DNA-binding and β-catenin-binding domains controlling context-specific Sox17/TCF4 complexes.

    Evidence EMSA, ChIP, reporter assays and mutagenesis in Wnt3A-stimulated airway epithelial cells

    PMID:20802155

    Open questions at the time
    • Determinants of activating vs. repressive complex composition not fully defined
  9. 2011 High

    Showed SOX17 is sufficient to confer fetal HSC identity, reprogramming adult HSCs to fetal self-renewal and output, with leukemogenesis upon prolonged expression.

    Evidence Retroviral overexpression with transplantation, flow cytometry, and expression profiling

    PMID:21828271

    Open questions at the time
    • Transcriptional targets driving fetal identity not enumerated
    • Mechanism of leukemic transformation unresolved
  10. 2012 High

    Established a cell-intrinsic vascular role: SOX17 upregulates VEGFR2 and promotes tumor angiogenesis and vessel destabilization, with deletion normalizing tumor vasculature.

    Evidence Bidirectional endothelial-specific genetic manipulation in tumor mouse models

    PMID:23241958

    Open questions at the time
    • Direct vs. indirect VEGFR2 regulation not defined here
    • Junctional destabilization mechanism addressed later
  11. 2013 High

    Positioned SOX17 in the arterial/hemogenic specification axis as acting downstream of canonical Wnt and upstream of Notch, required for arterial identity and hemogenic endothelium.

    Evidence Endothelial-specific conditional KO, Sox17-GFP reporter mice, ES cell differentiation, and Wnt/Notch epistasis

    PMID:23604320 PMID:24153254

    Open questions at the time
    • Direct Notch-pathway target genes of SOX17 not defined at this stage
  12. 2013 High

    Confirmed Wnt as a major upstream input maintaining Sox17 in endoderm via Tcf4/β-catenin occupancy of Sox17 cis-regulatory elements.

    Evidence Conditional β-catenin deletion, tetraploid rescue, lineage tracing, and ChIP in ES cell differentiation

    PMID:23824574

    Open questions at the time
    • Other endodermal inputs to Sox17 enhancers not delineated
  13. 2013 Medium

    Provided a tumor-suppressive Wnt-antagonism mechanism in glioma, where SOX17 forms β-catenin-TCF4-Sox17 complexes, lowers β-catenin, and promotes differentiation/apoptosis.

    Evidence Retroviral overexpression, Co-IP, Western blot, RT-PCR, flow cytometry in HOG cells

    PMID:23474492

    Open questions at the time
    • Single cell-line context
    • Mechanism of β-catenin reduction not biochemically defined here
  14. 2014 High

    Identified SOX17 as the master human PGC-specifying factor, mechanistically distinct from mouse, with BLIMP1 repressing somatic genes.

    Evidence hPGCLC induction with loss/gain-of-function and transcriptomics across multiple PSC lines

    PMID:25543152

    Open questions at the time
    • Direct SOX17 PGC target genes only partly mapped at this stage
    • Species divergence mechanism unknown
  15. 2014 High

    Defined SOX17 as a reversible switch maintaining intra-aortic HSC clusters, where exogenous expression sustains reconstitution and shutdown triggers differentiation.

    Evidence Inducible retroviral overexpression/shutdown with stromal co-culture and in vivo transplantation

    PMID:24662049

    Open questions at the time
    • Effector genes of the self-renewal/differentiation switch not identified
  16. 2014 High

    Resolved how SOX17 drives lineage conversion, mapping autoregulatory and feedforward network motifs sufficient for ESC-to-XEN conversion.

    Evidence Inducible expression with RNA-seq, ChIP-seq, and blastocyst injection

    PMID:25373912

    Open questions at the time
    • Cofactors stabilizing intermediate states not fully defined
  17. 2014 High

    Identified direct downstream effectors (Cer1, Hhex) of SOX17 in cardiac mesoderm specification, providing causal target genes.

    Evidence RNAi, ChIP, luciferase reporters, genome-wide profiling, and rescue experiments in mouse ESCs

    PMID:24585688

    Open questions at the time
    • How SOX17 selects these enhancers among genome-wide sites not defined
  18. 2014 High

    Extended SOX17 into β-cell secretory biology, showing it controls insulin trafficking networks and can rescue MODY4 secretory defects.

    Evidence Pancreas-specific deletion, inducible overexpression, EM/immunostaining, transcriptomics, and disease-model rescue

    PMID:25144761

    Open questions at the time
    • Direct trafficking-gene targets vs. indirect effects not fully distinguished
  19. 2014 High

    Distinguished post-transcriptional from transcriptional control of SOX17 by showing Notch restricts Sox17 mainly post-transcriptionally and SOX17 destabilizes endothelial junctions to drive tip-cell behavior.

    Evidence Endothelial deletion/overexpression, Notch ICD and Dll4 manipulation, retinal angiogenesis and junction imaging

    PMID:24755984

    Open questions at the time
    • Molecular mechanism of post-transcriptional Sox17 regulation not defined
    • Junctional/cytoskeletal targets not enumerated
  20. 2017 Medium

    Showed SOX17 reprograms endothelial transcription by retargeting Fli1 to nearby Sox sites, linking SOX17 to functional vascular integration.

    Evidence Retroviral overexpression in converted amniotic cells, transplantation, and genome-wide Fli1 ChIP-seq

    PMID:28091527

    Open questions at the time
    • Mechanism of Fli1 motif retargeting unresolved
    • Single-lab study
  21. 2017 High

    Provided a biliary tumor-suppressor mechanism, with SOX17 driving cholangiocyte differentiation and inhibiting Wnt-dependent proliferation, and Wnt3a suppressing SOX17 via DNMT.

    Evidence Overexpression/knockdown, xenografts, iPSC-cholangiocyte differentiation, reporter and DNMT-inhibition assays

    PMID:28237397

    Open questions at the time
    • Direct cilium-length and migration targets not mapped
  22. 2016 High

    Connected SOX17 loss to biliary barrier disease, showing biliatresone lowers GSH and SOX17 and that Sox17 knockdown recapitulates apical-polarity and barrier disruption.

    Evidence 3D cholangiocyte spheroids, bile duct explants, siRNA, GSH modulation, permeability assays

    PMID:27081925

    Open questions at the time
    • Direct link between GSH and SOX17 protein levels not mechanistically defined
  23. 2018 High

    Identified a uterine enhancer-level mechanism, with SOX17 acting through a distal Ihh enhancer (co-bound by GATA2/FOXA2/PGR) required for implantation.

    Evidence Uterine-specific deletion, in vivo CRISPR enhancer deletion, ChIP, and implantation assays

    PMID:30356064

    Open questions at the time
    • Functional contribution of each co-binding factor not dissected
  24. 2018 Medium

    Demonstrated direct transcriptional repression of β-catenin itself by SOX17 binding the β-catenin promoter, causing G0/G1 arrest in cervical cancer.

    Evidence qChIP, luciferase reporter, Western blot, cell-cycle analysis

    PMID:29970906

    Open questions at the time
    • Single cell-type context
    • Generality of promoter repression not established
  25. 2019 High

    Defined SOX17 as a fine-tuner of BBB permeability acting through positive induction of Wnt/β-catenin signaling in brain endothelium.

    Evidence Endothelial-specific inactivation, brain EC RNA-seq, and in vivo β-catenin destruction-complex inhibition

    PMID:30591003

    Open questions at the time
    • Direct Wnt-component targets of SOX17 in brain ECs not enumerated
  26. 2019 High

    Established an injury-regeneration circuit in which HIF-1α activates Sox17, which drives endothelial regeneration via Cyclin E1 after inflammatory vascular injury.

    Evidence Endothelial-specific deletion/overexpression, lineage tracing, HIF-1α modulation in an LPS model

    PMID:31073164

    Open questions at the time
    • Whether Cyclin E1 is a direct SOX17 target not resolved
  27. 2019 Medium

    Linked endothelial SOX17 to allergic airway inflammation, showing IL-33-induced SOX17 promotes monocyte adhesion via CCL2/ICAM-1 and ERK-STAT3.

    Evidence Endothelial-specific KO, OVA model, IL-33 neutralization, and human EC gain/loss-of-function

    PMID:30928652

    Open questions at the time
    • Direct vs. indirect CCL2/ICAM-1 regulation not defined
    • Single-lab study
  28. 2019 High

    Identified a context-specific genomic binding logic, showing seminoma SOX17 occupies compressed SOX17/OCT4 and noncomposite motifs distinct from somatic cells and maintains latent pluripotency factors.

    Evidence Comparative ChIP-seq, CRISPR/siRNA deletion, OCT4/AP staining in seminoma vs. somatic cells

    PMID:31583686

    Open questions at the time
    • Cofactors directing the seminoma-specific binding pattern not identified
  29. 2019 Medium

    Added a redox dimension, showing SOX17 directly represses the NRF2 promoter, sensitizing esophageal cancer cells to chemoradiation.

    Evidence ChIP-qPCR, luciferase reporter, overexpression, and xenografts in ESCC cells

    PMID:36310172

    Open questions at the time
    • Single-lab study
    • Physiological relevance beyond ESCC unaddressed
  30. 2020 Medium

    Demonstrated SOX17 requirement for coronary artery formation and direct activation of a Nestin enhancer in sprouting vessels.

    Evidence Inducible endothelial deletion, Nestin enhancer reporter, and coronary morphology analysis

    PMID:32921258

    Open questions at the time
    • Single-lab study
    • Broader coronary target program not mapped
  31. 2020 High

    Resolved the dual Wnt logic at genome scale, showing SOX17 and β-catenin co-occupy endodermal enhancers and either synergize Tcf-independently or repress Tcf-mediated transcription, making SOX17 a tissue-specific Wnt modifier.

    Evidence ChIP-seq, ATAC-seq, reporter assays, and epistasis in Xenopus gastrulae

    PMID:32894225

    Open questions at the time
    • Enhancer features dictating synergy vs. repression not fully predictive
  32. 2021 High

    Defined SOX17 as a master regulator of the CDX2/HOXA arterial-hematopoietic program in human hemogenic endothelium with lympho-myeloid potential.

    Evidence KO and inducible hPSCs with RNA-seq, ATAC-seq, ChIP for CDX2, and flow cytometry

    PMID:33596423

    Open questions at the time
    • Direct vs. indirect HOXA regulation downstream of CDX2 not fully separated
  33. 2021 High

    Placed GATA3/GATA2 upstream of SOX17 in BMP-driven hPGCLC specification, refining the germ-cell hierarchy.

    Evidence TF overexpression combinations, GATA KO epistasis, hPGCLC induction, xenogeneic ovaries

    PMID:33608411

    Open questions at the time
    • Direct GATA-to-SOX17 regulatory interaction not biochemically defined
  34. 2021 Medium

    Provided a disease-allele functional readout, showing the SOX17-Gln127* truncation abolishes both NOTCH1 activation and β-catenin inhibition.

    Evidence Dual-luciferase reporter assays with WT vs. mutant constructs

    PMID:33952808

    Open questions at the time
    • Single method, two targets only
    • Patient/in vivo validation not provided
  35. 2022 High

    Identified PAX8 as a direct physical and genomic partner of SOX17 in ovarian cancer, co-regulating cell-cycle and angiogenic genes including SERPINE1.

    Evidence Complex purification, Co-IP, ChIP-seq co-occupancy, angiogenesis assays, siRNA, mouse models

    PMID:35380877

    Open questions at the time
    • Whether PAX8-SOX17 cooperation is direct cofactor binding at shared sites not fully resolved
  36. 2022 High

    Connected SOX17 loss in PAH to HGF/c-Met activation, showing pharmacological c-Met inhibition reverses PAH features.

    Evidence Conditional endothelial KO, transcriptomics, HGF/c-Met inhibitor rescue in hypoxic PAH model

    PMID:36205124

    Open questions at the time
    • Whether SOX17 directly represses HGF not defined
  37. 2023 High

    Defined the regulatory-variant mechanism of PAH risk, showing upstream variants impair HOXA5/ROR-α binding to lower SOX17 and disrupt endothelial ECM and barrier function.

    Evidence CRISPR enhancer inhibition/deletion, allele-specific EMSA, siRNA, hPAEC transcriptomics, enhancer KO mice

    PMID:37066790

    Open questions at the time
    • Full set of SOX17-dependent ECM effectors not mapped
  38. 2023 High

    Linked SOX17 to endothelial bioenergetics and estrogen-related PAH susceptibility, showing it promotes oxidative phosphorylation, inhibits HIF-2α, and is repressed by 16α-hydroxyestrone.

    Evidence Seahorse assays, promoter luciferase, bidirectional endothelial mouse models, HIF-2α rescue, proteomics

    PMID:36913491

    Open questions at the time
    • Mechanism connecting SOX17 to mitochondrial OXPHOS not defined at the target-gene level
  39. 2023 High

    Identified E2F1 as a mediator of SOX17-deficiency-driven endothelial dysfunction, with E2F1 inhibition attenuating pulmonary hypertension.

    Evidence EC-specific KO/knockdown, scRNA-seq, RNA-seq, in vivo E2F1 inhibitor, luciferase

    PMID:37737027

    Open questions at the time
    • Whether SOX17 directly represses E2F1 not established
  40. 2023 Medium

    Described a paracrine exosomal mechanism by which SOX17 drives release of protective miR-224-5p/miR-361-3p that repress NR4A3 and PCSK9 to improve endothelial function.

    Evidence HPAEC overexpression/knockdown, exosome and miRNA functional assays, reporter assays, Su/hypoxia mouse model

    PMID:36919784

    Open questions at the time
    • Single-lab study
    • How SOX17 controls miRNA loading into exosomes not defined
  41. 2024 High

    Revealed an immune-evasion mechanism in colorectal cancer, where SOX17 engages a fetal intestinal program to suppress IFNγ sensing, lower MHC-I, and drive LGR5- immune-evasive tumor cells.

    Evidence CRISPR loss-of-function in AKP organoids, in vivo transplantation, transcriptomic/chromatin profiling, T-cell immunophenotyping

    PMID:38418875

    Open questions at the time
    • Direct SOX17 targets in the IFNγ/MHC-I axis not enumerated
  42. 2024 Medium

    Identified post-translational stabilization of SOX17 by the deubiquitinase UCHL1, promoting angiogenesis and blood-spinal cord barrier repair.

    Evidence IP-MS interaction mapping, UCHL1 conditional KO, in vivo Sox17 knockdown/overexpression rescue

    PMID:38478109

    Open questions at the time
    • Single-lab study
    • Ubiquitin sites on SOX17 and counteracting E3 ligase not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How SOX17 selects between Wnt activation, Wnt antagonism, and Wnt-independent functions in a given cell type, and which cofactors and chromatin features dictate this switch, remains the central unresolved question.
  • No unified model linking cofactor identity (β-catenin, TCF/LEF, PAX8, FLI1, OCT4) to activating vs. repressive outcomes
  • Structural basis of context-specific motif selection unknown
  • Direct target genes for many phenotypes remain unmapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 6 GO:0098772 molecular function regulator activity 3
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-1266738 Developmental Biology 6 R-HSA-162582 Signal Transduction 6 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-1474244 Extracellular matrix organization 1
Partners
CTNNB1FLI1PAX8POU5F1SMAD3TCF7L2UCHL1

Evidence

Reading pass · 46 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 SOX17 physically interacts with β-catenin via a conserved C-terminal motif in the SoxF subfamily, and this interaction potentiates SOX17-mediated transcriptional activation of endodermal target genes (Foxa1, Foxa2). The C-terminal motif is required both for target gene transactivation and β-catenin binding, analogous to TCF/LEF-β-catenin interactions. Co-immunoprecipitation, reporter/transactivation assays, deletion/mutation analysis in Xenopus embryos and cell lines Development High 15163629
2004 SOX17 directly binds two SOX-binding sites within the laminin α1 (Lama1) parietal-endoderm enhancer and trans-activates the enhancer in a DNA-binding (HMG box)-dependent manner. Trans-activation requires synergy between the two SOX sites and integrity of upstream Sp1/Sp3 and NF-Y binding sites. Reporter assays, EMSA, site-directed mutagenesis, Northern blot during F9 cell differentiation Journal of Biological Chemistry High 15220343
2007 SOX17 antagonizes β-catenin/TCF activity by physically interacting with TCF/LEF family members via its HMG box domain and by promoting proteasomal degradation of both β-catenin and TCF proteins through a GSK3β-independent mechanism that is blocked by proteasome inhibitors. Co-immunoprecipitation, reporter (TCF/LEF luciferase) assays, gain- and loss-of-function in SW480 colon carcinoma cells, proteasome inhibitor treatment, Western blot Molecular and Cellular Biology High 17875931
2006 SOX17 promotes oligodendrocyte progenitor cell (OPC) cycle exit and differentiation: siRNA-mediated knockdown increases OPC proliferation and reduces lineage progression, whereas overexpression in the presence of mitogen has opposite effects and directly stimulates MBP gene promoter activity. siRNA knockdown, overexpression, flow cytometry, reporter assay (MBP promoter), FACS-purified oligodendrocyte lineage cells from CNP-EGFP transgenic mice Journal of Neuroscience High 16988043
2007 SOX17 is required for fetal and neonatal hematopoietic stem cell (HSC) maintenance but not for adult HSCs. Germline or conditional deletion of Sox17 from hematopoietic cells abolishes fetal/neonatal definitive HSCs; Sox17 expression ceases ~4 weeks after birth, coinciding with the acquisition of adult HSC phenotype. Germline and conditional genetic deletion (Cre/lox), HSC phenotyping by flow cytometry, transplantation assays Cell High 17655922
2007 In embryonic stem cells, SOX17 is required for cardiac mesoderm specification: Sox17 shRNA suppresses cardiac myogenesis and blocks induction of Mesp1/Mesp2 and Hex, acting downstream of mesoderm formation but upstream of these cardiogenic transcription factors, and impairs cardiac myogenesis non-cell-autonomously. Lentiviral shRNA knockdown in differentiating ES cells, RT-PCR for lineage markers, cardiac differentiation assays PNAS Medium 17360443
2009 SOX17 promotes cell cycle progression and inhibits TGF-β/Smad3 signaling in respiratory epithelial cells: SOX17 physically interacts with Smad3 and blocks Smad3 DNA binding and transcriptional activity, enhances cyclin D1 expression (directly activating cyclin D1 promoter), and decreases TGF-β-responsive cell cycle inhibitors p15, p21, and p57. Conditional Sox17 expression in adult mouse lung, Co-IP (Sox17-Smad3 interaction), reporter assays (cyclin D1 promoter), RT-PCR, Western blot PLoS One High 19479035
2009 SOX17 is required cell-autonomously for biliary/gallbladder progenitor specification: in Sox17-null embryos the paired lateral endoderm domains giving rise to the gallbladder/bile duct are absent, and chimera analysis shows Sox17-null cells in the posteroventral foregut fail to acquire gallbladder/bile-duct molecular character. Sox17 knockout mouse, chimera analysis, in situ hybridization, whole-mount immunostaining Biochemical and Biophysical Research Communications High 19913509
2009 Oct4 switches from occupying the Sox2 promoter to the Sox17 promoter during BMP2-driven cardiac progenitor specification in human ES cells, activating Sox17 expression to generate an endodermal subset that releases Wnt and BMP2 paracrine signals for cardiogenesis. ChIP/promoter occupancy assays, transgenic Oct4 overexpression, conditional Sox17 modulation, paracrine conditioned-medium rescue experiments Journal of Cell Biology Medium 19736317
2010 SOX17 directly binds multiple sites in the Lef-1 promoter (independently and through TCF complexes) and suppresses Wnt3A/β-catenin-mediated transcriptional activation of Lef-1; the DNA-binding and β-catenin-binding domains of SOX17 control context-specific Sox17/TCF4 complex formation on the Lef-1 promoter. EMSA, ChIP, reporter assays, site-directed mutagenesis, Wnt3A stimulation of primary airway epithelial cells American Journal of Physiology - Lung Cellular and Molecular Physiology High 20802155
2011 Ectopic Sox17 expression in adult HSCs and transiently reconstituting multipotent progenitors confers fetal HSC characteristics including increased self-renewal, expression of fetal surface markers, and a fetal hematopoietic output pattern (increased erythropoiesis/myelopoiesis, decreased lymphopoiesis); prolonged ectopic Sox17 expression leads to leukemogenesis. Retroviral Sox17 overexpression, transplantation assays (long-term reconstitution), flow cytometry, gene expression profiling Genes & Development High 21828271
2012 SOX17 promotes tumor angiogenesis and vascular destabilization by upregulating VEGFR2 expression in a cell-intrinsic manner and promoting endothelial sprouting; conversely, Sox17 deletion in tumor endothelial cells normalizes tumor vessels and inhibits tumor growth and metastasis. Endothelial-specific Sox17 deletion and overexpression in genetic mouse models, tumor implantation, VEGFR2 expression analysis, drug delivery assays Journal of Clinical Investigation High 23241958
2013 SOX17 is required for arterial identity acquisition and maintenance: endothelial-specific Sox17 inactivation causes loss of arterial differentiation and vascular remodeling defects. SOX17 acts upstream of the Notch signaling system and downstream of the canonical Wnt system in arterial/venous specification. Endothelial-specific conditional Sox17 knockout in mouse embryo and postnatal retina, PECAM/DLL4/Notch marker analysis, epistasis with Wnt and Notch pathway components Nature Communications High 24153254
2013 SOX17 is expressed in haemogenic endothelium and is required for HSC development; in the ES cell differentiation model Sox17 plays a pivotal role in haemogenic endothelium development/expansion through the Notch signalling pathway. Sox17-GFP reporter mice, conditional Sox17 deletion, ES cell differentiation, Notch pathway analysis Nature Cell Biology High 23604320
2013 Wnt/β-catenin signaling maintains Sox17 expression in endoderm: conditional deletion of β-catenin in Sox17-positive lineages abolishes Sox17 expression in visceral endoderm and definitive endoderm, and Tcf4/β-catenin transactivation complexes accumulate on Sox17 cis-regulatory elements during endoderm induction in an ES cell differentiation system. Conditional β-catenin deletion, tetraploid rescue experiments, Sox17 lineage tracing, ChIP demonstrating Tcf4/β-catenin on Sox17 regulatory elements in ES cells Development High 23824574
2014 SOX17 is the key transcriptional regulator specifying human primordial germ cell (PGC) fate, whereas BLIMP1 represses endodermal and other somatic genes during specification. This is mechanistically distinct from mouse PGC specification, where SOX17 does not play this key role. hPGCLC induction from pluripotent stem cells, Sox17 loss-of-function and gain-of-function, transcriptomic analysis, marker expression Cell High 25543152
2014 SOX17 is required for the maintenance of intra-aortic HSC clusters and controls HSC fate between self-renewal and differentiation: forced expression of Sox17 in E10.5 AGM CD45low c-Kithi cells maintains cluster formation and long-term bone marrow reconstitution capacity in vitro and in vivo; shutdown of exogenous Sox17 triggers immediate hematopoietic differentiation. Retroviral Sox17 overexpression, co-culture with stromal cells, in vivo bone marrow transplantation, inducible Sox17 shutdown Molecular and Cellular Biology High 24662049
2014 Sox17 drives ESC-to-XEN (extraembryonic endoderm) cell fate conversion through autoregulatory and feedforward gene regulatory network motifs; transient Sox17 expression is sufficient to drive this conversion, with cells transiting through distinct intermediate states. Inducible Sox17 expression in ESCs, RNA-seq, ChIP-seq, blastocyst injection of converted XEN cells Cell Reports High 25373912
2014 Hhex and Cer1 are direct downstream effectors of Sox17 in the pathway for cardiac mesoderm specification in mouse ESCs: Sox17 is required for Hhex expression and directly occupies and transactivates the Cer1 promoter; Hhex is required (but insufficient) for Cer1; forced Cer1 rescues cardiac differentiation in Hhex-deficient cells. RNAi knockdown, ChIP, luciferase reporter assays, genome-wide Sox17-dependent gene profiling, rescue experiments Stem Cells High 24585688
2014 The Notch pathway restricts sprouting angiogenesis by reducing Sox17 expression mainly at the post-transcriptional level; Sox17 promotes endothelial migration by destabilizing endothelial junctions and rearranging cytoskeletal structure, and upregulates tip-cell-preferential genes. Endothelial Sox17 deletion rescues excessive tip cell formation under Notch inhibition. Endothelial-specific Sox17 deletion and overexpression, Notch ICD overexpression, Dll4 blockade, retinal angiogenesis analysis, endothelial junction/cytoskeleton imaging Circulation Research High 24755984
2015 Sox17 deletion in oligodendrocyte progenitor cells (OPCs) in vivo causes developmental hypomyelination and motor dysfunction through reduced Olig2+ and mature oligodendrocyte numbers; Notch signaling mediates Sox17's role in progenitor expansion, while TCF7L2 is involved in Sox17-regulated differentiation. Floxed Sox17 conditional knockout in oligodendroglial lineage, myelination and motor behavior analysis, Notch pathway analysis, TCF7L2 expression Cell Reports High 31801081
2016 Biliatresone decreases glutathione (GSH) and SOX17 protein levels in mouse cholangiocytes; GSH reduction is necessary and sufficient to mediate biliatresone's effects on cholangiocyte monolayer damage; Sox17 knockdown in 3D cholangiocyte spheroids mimics biliatresone's disruption of apical polarity and barrier integrity. 3D cholangiocyte spheroid culture, neonatal bile duct explants, siRNA knockdown of Sox17, GSH modulation, permeability assays (rhodamine efflux), α-SMA/collagen staining Hepatology High 27081925
2017 SOX17 regulates cholangiocyte differentiation and inhibits Wnt/β-catenin-dependent proliferation; in CCA cells, SOX17 overexpression inhibits migration, anchorage-independent growth, and Wnt/β-catenin signaling, and restores biliary markers and primary cilium length. Wnt3a decreases SOX17 expression in normal cholangiocytes via a DNMT-dependent mechanism. Lentiviral SOX17 overexpression/knockdown, xenograft models, iPSC-to-cholangiocyte differentiation, reporter assays, DNMT inhibition experiments Journal of Hepatology High 28237397
2018 SOX17 regulates uterine epithelial-stromal crosstalk by acting on a distal enhancer 19 kb upstream of the Ihh locus; CRISPR deletion of this SOX17-binding region reduces Ihh expression specifically in the uterus and impairs embryo implantation. The enhancer is also co-occupied by GATA2, FOXA2, and PGR. Uterine-epithelium-specific Sox17 deletion, CRISPR-Cas deletion of SOX17-binding enhancer region in vivo, ChIP, implantation assays Nature Communications High 30356064
2019 HIF-1α transcriptionally activates Sox17 expression following endotoxemia; Sox17 in turn increases endothelial cell proliferation by upregulating Cyclin E1, thereby mediating endothelial regeneration after inflammatory vascular injury. Endothelial-specific Sox17 deletion and overexpression, genetic lineage tracing, HIF-1α modulation, Cyclin E1 expression analysis, LPS endotoxemia model Nature Communications High 31073164
2019 SOX17 and β-catenin co-occupy Wnt-responsive enhancers across the endoderm genome; on some enhancers they synergistically activate transcription independently of Tcfs, while on others SOX17 represses β-catenin/Tcf-mediated transcription to restrict gene expression domains. Sox17 acts as a tissue-specific modifier of Wnt responses. Genomic approaches (ChIP-seq, ATAC-seq), epistasis experiments in Xenopus gastrulae, reporter assays, Sox17 loss-of-function eLife High 32894225
2019 SOX17 is a transcriptional repressor of NRF2: ChIP and promoter reporter analyses demonstrate that SOX17 directly binds the NRF2 promoter and suppresses its transcriptional activity, sensitizing ESCC cells to chemoradiation. ChIP-qPCR, luciferase reporter assay, SOX17 overexpression in ESCC cells, xenograft models Journal of Biomedical Science Medium 36310172
2019 SOX17 in seminoma-like cells binds canonical (SOX2/OCT4), compressed (SOX17/OCT4), and noncomposite SOX motifs—a binding pattern highly distinct from SOX17 binding in somatic cells (only 12% overlap). In seminoma cells, SOX17 maintains latent pluripotency by regulating TFAP2C, PRDM1, and PRDM14, and its deletion leads to loss of OCT4 protein and alkaline phosphatase activity. ChIP-seq comparing SOX17 binding in seminoma vs. somatic cells, CRISPR/siRNA SOX17 deletion, OCT4/AP staining International Journal of Cancer High 31583686
2021 SOX17 directly activates CDX2 expression in hemogenic endothelium (HE), leading to upregulation of the HOXA cluster genes; SOX17 is a master regulator of HOXA and arterial programs in HE and is required for specification of DLL4+CXCR4+ HE with robust lympho-myeloid potential. SOX17-knockout and SOX17-inducible human PSCs, molecular profiling (RNA-seq, ATAC-seq), ChIP for CDX2 target, flow cytometry Cell Reports High 33596423
2021 GATA3 or GATA2, acting as immediate BMP effectors, combined with SOX17 and TFAP2C, are required to generate hPGCLCs; GATA3/GATA2 knockouts dose-dependently impair BMP-induced hPGCLC specification, while GATA3/GATA2 expression is unaffected in SOX17, TFAP2C, or BLIMP1 knockouts, placing GATA factors upstream of SOX17 in the BMP-germ cell specification hierarchy. TF overexpression combinations in hPSCs, GATA3/GATA2 knockout, hPGCLC induction assays, xenogeneic reconstituted ovaries Life Science Alliance High 33608411
2022 PAX8 and SOX17 physically interact and co-occupy overlapping genomic regions in ovarian cancer cells; together they regulate a common set of downstream genes (cell cycle, tissue morphogenesis), and co-depletion of PAX8 or SOX17 inhibits cancer cell viability and angiogenic factor secretion, including suppression of SERPINE1. PAX8 protein complex purification, Co-IP confirming PAX8-SOX17 interaction, ChIP-seq showing co-occupancy, angiogenesis tubule/capillary assays, siRNA depletion, mouse models Science Signaling High 35380877
2022 SOX17 deficiency in pulmonary endothelial cells activates HGF/c-Met signaling: transcriptomic profiling of Sox17-deficient lung ECs shows upregulation of HGF (a c-Met ligand), and pharmacological inhibition of HGF/c-Met attenuates and reverses PAH features in both preventive and therapeutic settings. Conditional endothelial Sox17 deletion in mice, transcriptomic profiling, HGF/c-Met inhibitor pharmacological rescue in hypoxia-induced PAH model Circulation Research High 36205124
2023 Common PAH risk variants upstream of the SOX17 promoter impair binding of transcription factors HOXA5 and ROR-α, reducing SOX17 expression; SOX17 silencing in hPAECs alters extracellular matrix regulation, increases apoptosis/proliferation, and disrupts barrier function. SOX17 enhancer knockout mice show more severe hypoxia-induced pulmonary hypertension. CRISPR inhibition/deletion of SOX17 enhancer regions, EMSA demonstrating differential TF binding to risk vs. nonrisk alleles, siRNA knockdown, hPAEC transcriptomics, SOX17 enhancer KO mice Circulation High 37066790
2023 SOX17 promotes mitochondrial bioenergetics (oxidative phosphorylation) in pulmonary artery endothelial cells and attenuates PAH partly by inhibiting HIF-2α; 16α-hydroxyestrone represses SOX17 promoter activity, linking estrogen metabolism to SOX17-dependent PAH susceptibility. Seahorse metabolic assays, promoter luciferase assays, Sox17EC-/- and Sox17Tg mice in chronic hypoxia model, HIF-2α overexpression rescue, untargeted proteomics American Journal of Respiratory and Critical Care Medicine High 36913491
2023 E2F1 signaling mediates SOX17 deficiency-induced endothelial cell dysfunction and pulmonary hypertension: SOX17-deficient lung ECs show upregulated E2F1 target genes (cell cycle, proliferation, anti-apoptotic), and pharmacological inhibition of E2F1 attenuates pulmonary hypertension in EC-specific Sox17-knockout mice. EC-specific Sox17 conditional KO and Tie2Cre-mediated knockdown, single-cell RNA-seq, RNA-seq, E2F1 inhibitor (HLM006474) treatment in vivo, luciferase assay Hypertension High 37737027
2023 SOX17 overexpression promotes exosome-mediated autocrine release of miR-224-5p and miR-361-3p in pulmonary artery endothelial cells; these miRNAs are internalized by injured HPAECs and repress NR4A3 and PCSK9, improving endothelial function and attenuating pulmonary hypertension. SOX17 overexpression/knockdown in HPAECs, exosome isolation and characterization, miRNA overexpression/inhibition, NR4A3/PCSK9 reporter assays, Su/hypoxia mouse PAH model Advanced Science Medium 36919784
2024 SOX17 suppresses the ability of colorectal tumor cells to sense and respond to IFNγ by engaging a fetal intestinal transcriptional programme, driving differentiation from LGR5+ to LGR5- immune-evasive tumour cells with lower MHC-I expression; SOX17 loss in AKP organoid-derived tumours reduces tumour persistence in vivo and leads to IFNγ-producing effector CD8+ T cell infiltration. CRISPR SOX17 loss-of-function in engineered AKP organoids, in vivo colonoid transplantation, transcriptomic and chromatin profiling, IFNγ/MHC-I analysis, T cell immunophenotyping Nature High 38418875
2021 The nonsense mutation SOX17-Gln127* abolishes the ability of SOX17 to transcriptionally activate its target gene NOTCH1 and also eliminates SOX17's inhibitory effect on β-catenin function, as assessed by dual-luciferase reporter assay. Dual-luciferase reporter assay with wild-type vs. Gln127*-mutant SOX17 constructs for NOTCH1 and β-catenin transcriptional targets International Heart Journal Medium 33952808
2018 SOX17 trans-suppresses β-catenin expression in cervical cancer cells by directly binding to the β-catenin promoter, as confirmed by luciferase reporter assay and quantitative ChIP, thereby inhibiting Wnt/β-catenin signaling and causing cell cycle arrest at G0/G1. qChIP, luciferase reporter assay, Western blot, cell cycle analysis in cervical cancer cells Cell Death & Disease Medium 29970906
2024 The deubiquitinase UCHL1 physically interacts with SOX17 and stabilizes it (preventing proteasomal degradation), thereby promoting angiogenesis and blood-spinal cord barrier repair after spinal cord injury; UCHL1 conditional KO reduces Sox17 levels and impairs endothelial regeneration. Immunoprecipitation-mass spectrometry identifying UCHL1-SOX17 interaction, UCHL1 conditional KO mice, Sox17 knockdown/overexpression in vivo, rescue experiments Cellular and Molecular Life Sciences Medium 38478109
2017 Sox17 constitutive expression is required to confer endothelial morphogenesis gene expression and functional vascular integration of transplanted converted cells; enforced Sox17 expression shifts the genomic targeting of Fli1 to favour nearby Sox consensus sites, promoting EC function. Retroviral Sox17 overexpression in converted amniotic cells, transplantation into injured vessels, genome-wide Fli1 ChIP-seq showing motif shift Nature Communications Medium 28091527
2019 SOX17 in endothelial cells is regulated by IL-33 and promotes monocyte adhesion to endothelial cells by upregulating CCL2 and ICAM-1 and activating the ERK-STAT3 pathway; endothelium-specific Sox17 deletion alleviates OVA-induced allergic airway inflammation including airway hyperresponsiveness and immune cell infiltration. Endothelial-specific Sox17 knockout, OVA airway inflammation model, IL-33 neutralizing antibody, gain/loss-of-function in human ECs, cytokine/chemokine measurement Journal of Allergy and Clinical Immunology Medium 30928652
2019 SOX17 fine-tunes blood-brain barrier (BBB) permeability: endothelial-specific Sox17 inactivation increases brain microvascular permeability, and RNA-seq identifies Wnt/β-catenin pathway members as downstream targets of SOX17 in brain ECs; SOX17 positively induces Wnt/β-catenin signaling, and in vivo inhibition of the β-catenin destruction complex prevents the permeability increase caused by Sox17 loss. Endothelial-specific Sox17 inactivation, RNA-seq of brain ECs, β-catenin destruction complex inhibition in vivo, permeability assays Circulation Research High 30591003
2013 Sox17 overexpression in oligodendroglioma cells (HOG) increases β-catenin-TCF4-Sox17 complex formation, decreases total cellular β-catenin levels, promotes cell cycle exit and apoptosis, increases myelin protein expression, and upregulates SFRP1 while downregulating Wnt-1 and Frizzled-1, -3, -7; without endogenous Sox17, β-catenin is not associated with Sox17 protein despite high levels of both. Retroviral Sox17 overexpression in HOG cells, Co-IP (β-catenin-TCF4-Sox17 complex), Western blot, RT-PCR, flow cytometry Cancer Letters Medium 23474492
2014 SOX17 directly regulates secretory networks controlling insulin trafficking and secretion in pancreatic β cells: Sox17 deletion in the pancreas causes abnormal proinsulin trafficking and dilated secretory organelles, whereas overexpression in mature β cells causes precocious proinsulin secretion. A 24-hour pulse of SOX17 expression produces global transcriptional changes in hormone transport/secretion factors, and transient SOX17 overexpression reverses insulin secretory defects in MODY4 mice. Pancreas-specific Sox17 deletion, Ins2-rtTA inducible overexpression, proinsulin immunostaining/EM, MODY4 rescue experiment, transcriptomics PLoS One High 25144761
2020 SOX17 overexpression promotes endothelial integration into injured vessels and transcriptional activation of the Nestin enhancer in sprouting coronary vessels; conditional endothelial Sox17 deletion during coronary development causes deficient coronary artery formation. Genetic-inducible endothelial deletion of Sox17 (Nes-CreER), Nestin enhancer reporter, coronary vessel morphology analysis Circulation Research Medium 32921258

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 SOX17 is a critical specifier of human primordial germ cell fate. Cell 659 25543152
2007 Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 353 17655922
2007 Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Molecular and cellular biology 288 17875931
2004 Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development (Cambridge, England) 245 15163629
2009 Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Developmental cell 242 19619492
2013 Sox17 is indispensable for acquisition and maintenance of arterial identity. Nature communications 234 24153254
2008 Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. The Journal of pathology 190 18348160
2006 Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. Journal of cell science 175 16895970
2007 Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos. Biochemical and biophysical research communications 154 17610846
2007 Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 146 17360443
2013 The expression of Sox17 identifies and regulates haemogenic endothelium. Nature cell biology 133 23604320
2010 SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics 124 20716954
2018 Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome medicine 122 30029678
2012 SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clinical chemistry 119 23136251
2006 Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. The Journal of neuroscience : the official journal of the Society for Neuroscience 117 16988043
2019 Sox17 is required for endothelial regeneration following inflammation-induced vascular injury. Nature communications 108 31073164
2011 Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors. Genes & development 107 21828271
2002 Molecular cloning and characterization of human SOX17. International journal of molecular medicine 100 11786926
2012 Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. The Journal of clinical investigation 95 23241958
2009 Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate. The Journal of cell biology 92 19736317
2016 The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis through decreased glutathione and SOX17. Hepatology (Baltimore, Md.) 91 27081925
2017 SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of hepatology 89 28237397
2012 Role of SOX17 in hematopoietic development from human embryonic stem cells. Blood 89 23169777
2013 Wnt/β-catenin signalling regulates Sox17 expression and is essential for organizer and endoderm formation in the mouse. Development (Cambridge, England) 85 23824574
2009 Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice. Development (Cambridge, England) 84 19515696
2009 Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast cancer research and treatment 83 19301122
2024 SOX17 enables immune evasion of early colorectal adenomas and cancers. Nature 81 38418875
2015 Sox7, Sox17, and Sox18 Cooperatively Regulate Vascular Development in the Mouse Retina. PloS one 81 26630461
2010 Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. International journal of oncology 81 20043076
2016 SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer. Clinical chemistry and laboratory medicine 77 26741346
2014 Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis. Circulation research 76 24755984
2018 SOX17 regulates uterine epithelial-stromal cross-talk acting via a distal enhancer upstream of Ihh. Nature communications 74 30356064
2019 Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier. Circulation research 71 30591003
2006 Sox17 influences the differentiation of respiratory epithelial cells. Developmental biology 68 16574095
2004 SOX7 and SOX17 regulate the parietal endoderm-specific enhancer activity of mouse laminin alpha1 gene. The Journal of biological chemistry 68 15220343
2009 Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology 67 19549530
2015 Deficiency of endothelium-specific transcription factor Sox17 induces intracranial aneurysm. Circulation 66 25596186
2012 Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. The Journal of molecular diagnostics : JMD 60 22921431
2009 Differential expression of SOX2 and SOX17 in testicular germ cell tumors. American journal of clinical pathology 57 19369635
2015 The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. Oncotarget 56 25868860
2013 Sox17 haploinsufficiency results in perinatal biliary atresia and hepatitis in C57BL/6 background mice. Development (Cambridge, England) 56 23293295
2018 SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer. Cell death & disease 54 29970906
2012 SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discovery medicine 53 22846201
2021 GATA transcription factors, SOX17 and TFAP2C, drive the human germ-cell specification program. Life science alliance 51 33608411
2019 SOX17 in cellular reprogramming and cancer. Seminars in cancer biology 51 31419525
2014 Sox17-mediated XEN cell conversion identifies dynamic networks controlling cell-fate decisions in embryo-derived stem cells. Cell reports 51 25373912
2011 Sox17 regulates proliferation and cell cycle during gastric cancer progression. Cancer letters 51 21514720
2015 Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival. Journal of applied genetics 50 26337424
2012 Dual lineage-specific expression of Sox17 during mouse embryogenesis. Stem cells (Dayton, Ohio) 50 22865702
2009 Sox17 promotes cell cycle progression and inhibits TGF-beta/Smad3 signaling to initiate progenitor cell behavior in the respiratory epithelium. PloS one 50 19479035
2016 SOX17 is a tumor suppressor in endometrial cancer. Oncotarget 45 27738313
2022 The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. Science signaling 44 35380877
2011 Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 43 22161215
2013 Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer letters 42 23474492
2022 Sox17 Deficiency Promotes Pulmonary Arterial Hypertension via HGF/c-Met Signaling. Circulation research 41 36205124
2019 SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes. Journal of biomedical science 41 30777052
2020 Sox17 and β-catenin co-occupy Wnt-responsive enhancers to govern the endoderm gene regulatory network. eLife 38 32894225
2019 Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate. International journal of cancer 38 31583686
2016 Mouse Sox17 haploinsufficiency leads to female subfertility due to impaired implantation. Scientific reports 36 27053385
2021 SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. Cell reports 35 33596423
2009 Expression and function of mouse Sox17 gene in the specification of gallbladder/bile-duct progenitors during early foregut morphogenesis. Biochemical and biophysical research communications 34 19913509
2011 The Sox17-mCherry fusion mouse line allows visualization of endoderm and vascular endothelial development. Genesis (New York, N.Y. : 2000) 33 22121118
2023 SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation 32 37066790
2013 SOX17 is expressed in regenerating oligodendrocytes in experimental models of demyelination and in multiple sclerosis. Glia 32 23918253
2019 Endocardium differentiation through Sox17 expression in endocardium precursor cells regulates heart development in mice. Scientific reports 31 31420575
2010 Contrasting effects of Sox17- and Sox18-sustained expression at the onset of blood specification. Blood 31 20228271
2023 SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics. American journal of respiratory and critical care medicine 30 36913491
2023 SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 30 36919784
2023 Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 28 36788073
2020 Sox17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels. Circulation research 27 32921258
2019 SOX17 Inhibits Tumor Metastasis Via Wnt Signaling In Endometrial Cancer. OncoTargets and therapy 27 31632077
2014 Sox17-mediated maintenance of fetal intra-aortic hematopoietic cell clusters. Molecular and cellular biology 27 24662049
2003 Molecular cloning and expression of Sox17 in gonads during sex reversal in the rice field eel, a teleost fish with a characteristic of natural sex transformation. Biochemical and biophysical research communications 27 12659838
2021 The pathophysiological role of novel pulmonary arterial hypertension gene SOX17. The European respiratory journal 26 33632800
2013 Transgenic overexpression of Sox17 promotes oligodendrocyte development and attenuates demyelination. The Journal of neuroscience : the official journal of the Society for Neuroscience 26 23884956
2010 Sox17 modulates Wnt3A/beta-catenin-mediated transcriptional activation of the Lef-1 promoter. American journal of physiology. Lung cellular and molecular physiology 26 20802155
2017 Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia. Development (Cambridge, England) 25 28432216
2014 Hhex and Cer1 mediate the Sox17 pathway for cardiac mesoderm formation in embryonic stem cells. Stem cells (Dayton, Ohio) 25 24585688
2022 An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis. Communications biology 24 36344664
2020 MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. Hepatology (Baltimore, Md.) 23 31863486
2010 Sox17 and chordin are required for formation of Kupffer's vesicle and left-right asymmetry determination in zebrafish. Developmental dynamics : an official publication of the American Association of Anatomists 23 20925124
2014 Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 22 25106407
2023 SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 21 36853778
2022 SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer. Oncogene 21 35124696
2014 Sox17 regulates insulin secretion in the normal and pathologic mouse β cell. PloS one 21 25144761
2022 Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. Journal of biomedical science 20 36310172
2021 SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension. International heart journal 20 33952808
2019 SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma. Histopathology 20 31444787
2017 Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nature communications 19 28091527
2023 Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer. Cancer letters 18 37866545
2021 A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer. Diagnostic pathology 18 34006305
2020 Gallbladder wall abnormality in biliary atresia of mouse Sox17+/- neonates and human infants. Disease models & mechanisms 18 31996362
2024 Deubiquitinase UCHL1 promotes angiogenesis and blood-spinal cord barrier function recovery after spinal cord injury by stabilizing Sox17. Cellular and molecular life sciences : CMLS 17 38478109
2023 E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension. Hypertension (Dallas, Tex. : 1979) 17 37737027
2020 Human yolk sac-like haematopoiesis generates RUNX1-, GFI1- and/or GFI1B-dependent blood and SOX17-positive endothelium. Development (Cambridge, England) 17 33028609
2016 SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line. Cancer cell international 17 27065754
2023 An engineered Sox17 induces somatic to neural stem cell fate transitions independently from pluripotency reprogramming. Science advances 16 37611093
2019 Endothelial Sox17 promotes allergic airway inflammation. The Journal of allergy and clinical immunology 16 30928652
2017 Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget 16 28978154
2019 Sox17 Regulates a Program of Oligodendrocyte Progenitor Cell Expansion and Differentiation during Development and Repair. Cell reports 15 31801081

Missed literature

Know a paper Affinage missed for SOX17? Flag it for the maintainers and the community.

No submissions yet.